Upsher-Smith debuts generic Pepcid
Famotidine Oral Suspension had a market value of approximately $73 million for the 12 months ending June 2023, per IQVIA.
Upsher-Smith is offering Famotidine for Oral Suspension, which is the generic of Merck’s Pepcid oral suspension. The brand drug has been discontinued.
Upsher-Smith's launch is the result of Upsher-Smith’s strategic partnership with Appco Pharma, a New Jersey-based generic drug development and manufacturing company.
[Read more: Upsher-Smith expands Vigadrone product line]
Famotidine Oral Suspension had a market value of approximately $73 million for the 12 months ending June 2023, per IQVIA.
[Read more: Upsher-Smith extends fluoxetine product line]